Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 8, pp 2418–2427 | Cite as

Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas

  • Ulrike Heger
  • Leila Sisic
  • Henrik Nienhüser
  • Susanne Blank
  • Ulf Hinz
  • Georg Martin Haag
  • Katja Ott
  • Alexis Ulrich
  • Markus W. Büchler
  • Thomas Schmidt
Gastrointestinal Oncology
  • 150 Downloads

Abstract

Background

Only a few studies have analyzed multimodal treatment concepts in the subgroup of signet-ring-cell containing upper gastrointestinal (GI) cancer. Recent retrospective, multicentric data favor primary resection without neoadjuvant chemotherapy for gastric signet-ring-cell containing carcinomas (SRCs). We compared the outcomes of primarily resected carcinomas with neoadjuvantly treated, locally advanced esophagogastric SRCs.

Methods

A total of 310 patients with esophagogastric SRC-staged cT3/4/Nany/Many from a prospective unicentric database were included in this study; 192 (61.9%) received neoadjuvant therapy (NEO group) and 118 (38.1%) were primarily resected (RES group).

Results

Overall, 128 (41.3%) patients presented with adenocarcinoma of the esophagogastric junction (AEG) and 182 (58.7%) presented with gastric cancer. Neoadjuvant therapy was significantly associated with resection in curative intent (NEO: 91.1%; RES: 75.4%; P = 0.001), improved (y)pT category (P = 0.035), improved (y)pN category (P < 0.001), and R0 resections (curative intent cohort: 76.0% in NEO vs. 60.7% in RES; P = 0.010), among others, but not with postoperative complications. Overall survival was significantly improved by neoadjuvant treatment {median survival 28.5 months (95% confidence interval [CI] 14.4–39.6) vs. RES: 14.9 months (10.6–17.5); P < 0.001}, as well as in subgroups (AEG and gastric tumors, R0-resected patients, and patients with and without relevant comorbidities). Independent prognostic factors were neoadjuvant therapy (hazard ratio [HR] 0.66; P = 0.023), pT4 category (HR 1.71; P = 0.041), pN2 category (HR 1.86; P = 0.013), pN3 category (HR 2.40; P < 0.001), pM1 category (HR 1.95; P = 0.003), age > 70 years (HR 1.79; P = 0.006), gastric localization (HR 0.69; P = 0.032), American Society of Anesthesiologists classification 3/4 (HR 1.71; P = 0.004), and incomplete resection R1/2 (HR 1.6; P = 0.014).

Conclusions

Our results demonstrate a survival advantage for advanced-stage esophagogastric SRC patients by neoadjuvant treatment.

Notes

Funding

Leila Sisic received funding through a grant from the Faculty of Medicine, University of Heidelberg, however this has no relationship to the submitted work.

Supplementary material

10434_2018_6541_MOESM1_ESM.docx (801 kb)
Supplementary material 1 (DOCX 800 kb)

References

  1. 1.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010; 28: 5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681–92.CrossRefPubMedGoogle Scholar
  4. 4.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas PAjani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999; 229: 303–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21: 4604–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Schmidt T, Sicic L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014; 110: 1712–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Moehler M, Baltin CT, Ebert M, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015; 18: 550–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Kleinberg L, Brock MGibson M. Management of locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: finally a consensus. Curr Treat Options Oncol. 2015; 16: 35.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011; 254: 684–93; discussion 93.Google Scholar
  11. 11.
    Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014; 21: 1739–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014; 21: 1678–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1945–52.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rougier P, Mahjoubi M, Lasser P, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma: a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer. 1994; 30A: 1269–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Takiuchi H, Hirata I, Kawabe S, Egashira YKatsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep. 2000; 7: 841–6.PubMedGoogle Scholar
  16. 16.
    Charalampakis N, Nogueras Gonzalez GM, Elimova E, et al. The proportion of signet ring cell component in patients with localized gastric adenocarcinoma correlates with the degree of response to pre-operative chemoradiation. Oncology. 2016; 90: 239–47.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lorenzen S, Blank S, Lordick F, Siewert JROtt K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012; 19: 2119–27.CrossRefPubMedGoogle Scholar
  18. 18.
    Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Annals of Surgical Oncology. 2010; 17: 2733–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Heger U, Bader F, Lordick F, et al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2014; 17: 478–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Blank S, Schmidt T, Heger P, et al. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer. 2018;21(2):303–314.CrossRefPubMedGoogle Scholar
  21. 21.
    Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003; 98: 1521–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Sisic L, Strowitzki MJ, Blank S, et al. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric Cancer. 2018;21(3):552–568.CrossRefPubMedGoogle Scholar
  23. 23.
    Chirieac LR, Swisher SG, Correa AM, et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005; 11: 2229–36.CrossRefPubMedGoogle Scholar
  24. 24.
    Enlow JM, Denlinger CE, Stroud MR, Ralston JSReed CE. Adenocarcinoma of the esophagus with signet ring cell features portends a poor prognosis. Ann Thorac Surg. 2013; 96: 1927–32.CrossRefPubMedGoogle Scholar
  25. 25.
    Piessen G, Messager M, Leteurtre E, Jean-Pierre TMariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009; 250: 878–87.CrossRefPubMedGoogle Scholar
  26. 26.
    Bekkar S, Gronnier C, Messager M, et al. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Ann Thorac Surg. 2014; 97: 303–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Seevaratnam R, Cardoso R, McGregor C, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012; 15 Suppl 1: S3–18.CrossRefPubMedGoogle Scholar
  28. 28.
    Springfeld C, Wiecha C, Kunzmann R, et al. Influence of different neoadjuvant chemotherapy regimens on response, prognosis, and complication rate in patients with esophagogastric adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S905–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Al-Batran SE, Pauligk C, Homann N, et al. LBA27_PR Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Annals of Oncology. 2017; 28: mdx440.019–mdx440.019.Google Scholar
  30. 30.
    Piessen G, Messager M, Le Malicot K, et al. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas–PRODIGE 19–FFCD1103–ADCI002. BMC Cancer. 2013; 13: 281.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Piessen G, Messager M, Lefevre JH, et al. Signet ring cell adenocarcinomas: different clinical-pathological characteristics of oesophageal and gastric locations. Eur J Surg Oncol. 2014; 40: 1746–55.CrossRefPubMedGoogle Scholar
  32. 32.
    Nafteux PR, Lerut TE, Villeneuve PJ, et al. Signet ring cells in esophageal and gastroesophageal junction carcinomas have a more aggressive biological behavior. Ann Surg. 2014; 260: 1023–9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of General, Visceral and Transplant SurgeryUniversity HospitalHeidelbergGermany
  2. 2.National Center for Tumor Diseases (NCT)University HospitalHeidelbergGermany
  3. 3.Department of SurgeryRosenheimGermany

Personalised recommendations